drugset / Trial / NCT06660810

Neoadjuvant Intralesional Injection of Talimogene Laherparepvec

NCT06660810

Phase 2 Active not recruiting 2 enrolled John Rieth Amgen · collab
NaSingle-groupOpen-labelTreatment

Summary

The proposed study is designed to treat locally advanced soft tissue sarcoma (STS) subtypes with neoadjuvant talimogene laherparepvec (TVEC) and preoperative external beam radiation therapy (EBRT).

Timeline

Start
2025-03-03
Primary completion
2026-05-26
Completion
2031-02-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Talimogene Laherparepvec Other / unclassified Other

Indications